GSK Licenses Interleukin-6 Antibody from EUSA
EUSA Pharma (Oxford, UK) has out-licensed the exclusive worldwide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK, Middlesex, UK) for consideration of up to $44 million
EUSA Pharma (Oxford, UK) has out-licensed the exclusive worldwide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK, Middlesex, UK) for consideration of up to $44 million. As part of the agreement, EUSA will pay approximately 50% of the overall consideration to Vaccinex Inc. (Rochester, NY), its development partner for the antibody. GSK will fund and conduct all future development, production, and commercialization of the product.
Interleukin-6 is a pro-inflammatory cytokine and B-cell growth factor and acts as a resistance factor to standard chemotherapy. EUSA’s product, OP-R003, is the first fully human anti-interleukin-6 antibody, with target indications in oncology and inflammatory diseases. OP-R003 is derived from a first generation murine antibody, elsilimomab, which has achieved promising clinical results as a lymphoma therapy.
As a fully human antibody, OP-R003 has the potential to offer improved tolerability and a superior safety profile.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
